Targeted therapy in BRAF-mutated lung adenocarcinoma
Mené sur 84 patients atteints d'un cancer avancé du poumon non à petites cellules présentant la mutation V600E du gène BRAF, cet essai multicentrique non randomisé évalue l'efficacité, du point de vue de la réponse globale, et la toxicité du dabrafénib
Lung cancer is the most common cause of cancer death worldwide, and adenocarcinoma is the most common subtype. The improved outcomes seen with targeted therapies compared with chemotherapy in molecularly selected patients have transformed the management of adenocarcinoma of the lung. Testing is now routine for EGFR mutations and ALK rearrangements, and approved agents targeting both these oncogenic drivers are available.
The Lancet Oncology 2016